 "Wockhardt chairman Habil Khorakiwala")
Wockhardt's US business has suffered another jolt with the US drug regulator issuing a warning letter to the company's Morton Grove manufacturing plant in that country.
Three of its plants in India are already under an import alert and FDA's latest action means that Wockhardt will not receive approvals for products filed from the Morton Grove plant in the US.
Wockhardt said it was addressing issues raised by the regulator. In a notification to the exchange on Wednesday, it said the warning letter "would mean that current portfolio of the company will continue to be made available in the market. However, new
